BMC Gastroenterology
Cure8 research brief
Why This Matters
This study compares many targeted IBD drugs indirectly to help clarify how subcutaneous vedolizumab stacks up against other biologics and newer oral therapies — information that could inform treatment discussions for people with moderate‑to‑severe ulcerative colitis.
Who Should Pay Attention
Clinicians making treatment choices for moderate‑to‑severe ulcerative colitis; researchers interested in comparative effectiveness; patients considering or on biologic or novel oral IBD therapies.
Study Snapshot
Story typeResearch paper
Evidence typeResearch paper
Source depthMetadata only
What To Know
This open‑access network meta‑analysis (NMA) compares subcutaneous vedolizumab 108 mg every 2 weeks (SC) with multiple targeted therapies for moderate‑to‑severe ulcerative colitis using data from 29 randomized trials.
The authors report that vedolizumab SC had similar or superior efficacy to most comparators for maintenance of clinical response and remission, with lower odds of overall adverse events and overall infections versus several agents. Intravenous and subcutaneous vedolizumab were reported as equivalent in efficacy and safety.
The analysis is Bayesian and includes adjustments to harmonize differing trial designs; it is sponsored by Takeda Pharmaceuticals and conducted by authors with industry affiliation. The paper includes supplementary material with additional methods and results.
If you are reading this as a patient, note that NMAs use indirect comparisons and cannot replace head‑to‑head trials; individual treatment decisions depend on many factors beyond average efficacy and safety from pooled data.
Keep In Mind
Because this is an indirect network meta‑analysis (not a head‑to‑head randomized trial), differences may reflect trial design and population variations despite statistical adjustments. The study was funded by Takeda, the manufacturer of vedolizumab, which is an important conflict‑of‑interest disclosure to consider when interpreting results.
Source Details
Review the original publication for the complete reporting, methods, and context.
Research paper
Evidence type derived from source or registry metadata.
PublicationBMC Gastroenterology
PublisherSpringer Science and Business Media LLC
AuthorsJeanne Jiang, Abigail Wojtowicz, Jennifer Uyei +3 more
Study typeJournal Article
Indexed viaCrossref
Source typeResearch paper
PublishedJul 25, 2026, 12:00 AM
Content availableMetadata only
Funding disclosed by the source: Takeda Pharmaceuticals U.S.A., Inc
This Cure8 brief is based on source text from the linked article. Cure8 is informational only and is not a substitute for professional medical advice, diagnosis, or treatment.
Autologous Stem Cell Transplant for Crohn's Disease
This trial is testing whether adding vedolizumab after autologous stem cell transplant can improve remission rates for people with severe Crohn's disease that has failed multiple therapies.
When are biologic drugs an option for Crohn’s disease?
Biologics are a common and important treatment option for people with moderate to severe Crohn’s disease; knowing when they’re used and their potential risks helps patients discuss treatment choices with their care team.
Comparison of the Efficacy of Different Biologic Agents in Preventing Postoperative Endoscopic Recurrence of Crohn's Disease
The study is comparing common biologics given after Crohn's surgery to prevent endoscopic recurrence—a key issue for people who have had bowel resection. Knowing which drugs perform better in real‑world practice could...